N/A
Completed N=174
TOF-18F-FDG-PET/CT in Patients With Suspected Pancreatic Cancer
Pancreatic Cancer · Acute Pancreatitis · IPMN
Source: ClinicalTrials.gov NCT03914950 ↗
Enrolled (actual)
174
Serious AEs
0.0%
Results posted
May 2020
Primary outcomePrimary: SUVmax (Maximal Standard Uptake Value) Measurement 30 and 90 Min p.i. (Post Injection) — 0.77; 0.78; 0.81; 0.8 SUVmax — p=0.78
Summary
Aim of the prospective study is a better differentiation of benign and malignant lesions in the pancreas in patients with suspected pancreatic cancer using images 30 and 90 min p.i. (post injectionen) and a diagnostic CT (computed tomography) scan of the abdomen within the Time of Flight (TOF)-18F-FDG-PET/CT and thus an improvement of the quality of PET/CT findings.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY SUVmax (Maximal Standard Uptake Value) Measurement 30 and 90 Min p.i. (Post Injection) |
0.77; 0.78; 0.81; 0.8 | 0.78 |
| PRIMARY Participants With Increased Tracer Uptake Over the Pancreatic Lesion With and Without TOF |
116; 101 | — |
| SECONDARY Lesion Size |
3.0 | — |
Eligibility Criteria
Inclusion Criteria
- patients with suspected pancreatic cancer
Exclusion Criteria
- persons under 18 years of age
- patients with blood glucose level ≥160 mg/dl at the time of the PET/CT examination
- patients who will not be operated or biopsied and in which thus there are no histopathological findings of the pancreas
- pregnant women
Data sourced from ClinicalTrials.gov (NCT03914950). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.